Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190655 | 0.87 | LPL (0.43) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL24630498 | 0.87 | LPL (0.46) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL29842912 | 0.83 | LPL (0.40) | LPLLIPGJAK2BTKCD44 | |
| SCHEMBL190545 | 0.83 | LPL (0.40) | LPLLIPGJAK2BTKCD44 | |
| SCHEMBL2301628 | 0.81 | JAK2 (0.43) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL19004923 | 0.81 | LPL (0.42) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL31380588 | 0.81 | LPL (0.46) | LPLLIPGCD44CA1CA2 | |
| SCHEMBL168780 | 0.81 | LPL (0.46) | LPLLIPGCD44CA1CA2 | |
| SCHEMBL13601620 | 0.80 | LPL (0.41) | LPLLIPGJAK2BTKCA1 | |
| SCHEMBL29503402 | 0.80 | CYP3A4 (0.46) | LPLLIPGJAK2BTKCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250206747-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2025-06-26 | — | — | US | disclosed |
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| WO-2025043350-A1 | TRIAZOLOPYRIDOPYRIMIDINE AND DIHYDROIMIDAZOPYRIDOPYRIMIDINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025043349-A1 | PYRIMIDOPYRIDONE AND PTERIDONE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2025-03-06 | — | — | WO | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053901-A1 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | SIGNUM BIOSCIENCES, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | LPL 4216/4885LIPG 3781/4885JAK2 11/4885 |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | LPL 1874/4885LIPG 922/4885JAK2 353/4885 |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | LPL 1483/4885LIPG 3084/4885JAK2 887/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | LPL 3486/4885LIPG 2585/4885JAK2 170/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LPL 2236/4885LIPG 1666/4885JAK2 451/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | LPL 293/4885LIPG 204/4885JAK2 110/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | LPL 2085/4885LIPG 3333/4885JAK2 390/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | LPL 4247/4885LIPG 3461/4885JAK2 560/4885 |
| US-20110053901-A1 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | MPO, CYSLTR1, HNMT | LPL 1205/4885LIPG 577/4885JAK2 631/4885 |
| US-20250206747-A1 | COELENTERAZINE ANALOGUES | GLB1, AADAC, SI | LPL 664/4885LIPG 1073/4885JAK2 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.